Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yogesh Verma

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Science Translational Medicine|April 30, 2025
A thin cryobiopsy device compatible with transnasal endoscopy for the gastrointestinal tractDavid O Otuya, Hamid Farrokhi, Yogesh Verma, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccinationSylla G Malvi, Pulikkottil O Esmy, Richard Muwonge, et al.
Human Vaccines & Immunotherapeutics|December 11, 2023
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccineNeerja Bhatla, Richard Muwonge, Sylla G Malvi, et al.
Plos One|December 29, 2020
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort studyRichard Muwonge, Partha Basu, Tarik Gheit, et al.
The Lancet. Oncology|October 11, 2021
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort studyPartha Basu, Sylla G Malvi, Smita Joshi, et al.
Vaccine|November 29, 2022
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccinationSmita Joshi, Devasena Anantharaman, Richard Muwonge, et al.
Papillomavirus Research (Amsterdam, Netherlands)|March 27, 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in IndiaNeerja Bhatla, Bhagwan M Nene, Smita Joshi, et al.
Cancer Causes & Control : CCC|September 4, 2015
Report from a symposium on catalyzing primary and secondary prevention of cancer in IndiaSuneeta Krishnan, Preet K Dhillon, Afsan Bhadelia, et al.
The Lancet. Oncology|December 15, 2015
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyRengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, et al.
Papillomavirus Research (Amsterdam, Netherlands)|February 4, 2019
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort studyPartha Basu, Richard Muwonge, Neerja Bhatla, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Science Translational Medicine|April 30, 2025
A thin cryobiopsy device compatible with transnasal endoscopy for the gastrointestinal tractDavid O Otuya, Hamid Farrokhi, Yogesh Verma, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccinationSylla G Malvi, Pulikkottil O Esmy, Richard Muwonge, et al.
Human Vaccines & Immunotherapeutics|December 11, 2023
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccineNeerja Bhatla, Richard Muwonge, Sylla G Malvi, et al.
Plos One|December 29, 2020
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort studyRichard Muwonge, Partha Basu, Tarik Gheit, et al.
The Lancet. Oncology|October 11, 2021
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort studyPartha Basu, Sylla G Malvi, Smita Joshi, et al.
Vaccine|November 29, 2022
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccinationSmita Joshi, Devasena Anantharaman, Richard Muwonge, et al.
Papillomavirus Research (Amsterdam, Netherlands)|March 27, 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in IndiaNeerja Bhatla, Bhagwan M Nene, Smita Joshi, et al.
Cancer Causes & Control : CCC|September 4, 2015
Report from a symposium on catalyzing primary and secondary prevention of cancer in IndiaSuneeta Krishnan, Preet K Dhillon, Afsan Bhadelia, et al.
The Lancet. Oncology|December 15, 2015
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyRengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, et al.
Papillomavirus Research (Amsterdam, Netherlands)|February 4, 2019
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort studyPartha Basu, Richard Muwonge, Neerja Bhatla, et al.
Pageof 3